Asset
Zirdafulven, (S)-
Lantern Pharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06132503 | phase1 | recruiting | 2023-01-03 | 2028-11-30 | Lantern Pharma Inc. | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.